Exendin-(9–39) Corrects Fasting Hypoglycemia in SUR-1–/– Mice by Lowering cAMP in Pancreatic β-Cells and Inhibiting Insulin Secretion
Open Access
- 1 September 2008
- journal article
- Published by Elsevier BV
- Vol. 283 (38), 25786-25793
- https://doi.org/10.1074/jbc.m804372200
Abstract
No abstract availableThis publication has 41 references indexed in Scilit:
- Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMPProceedings of the National Academy of Sciences of the United States of America, 2007
- Metabolic and ionic coupling factors in amino acid-stimulated insulin release in pancreatic β-HC9 cellsAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Protein-sensitive hypoglycemia without leucine sensitivity in hyperinsulinism caused by KATP channel mutationsThe Journal of Pediatrics, 2006
- Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitusThe International Journal of Biochemistry & Cell Biology, 2006
- Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humansAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Exendin-(9-39) Is an Inverse Agonist of the Murine Glucagon-Like Peptide-1 Receptor: Implications for Basal Intracellular Cyclic Adenosine 3',5'-Monophosphate Levels and -Cell Glucose CompetenceEndocrinology, 1998
- Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.JCI Insight, 1998
- Glucagon-like peptide-1 is a physiological incretin in rat.JCI Insight, 1995
- Calcium-independent potentiation of insulin release by cyclic AMP in single β-cellsNature, 1993
- Influence of insulin on cyclic 3?,5?-AMP phosphodiesterase activity in liver, skeletal muscle, adipose tissue, and kidneyDiabetologia, 1968